To test the hypothesis that platelet activation is present cessful treatment of hypertension with the ACE inhibitor in hypertension, we measured plasma markers beta quinapril. We suggest that reversible platelet activation thromboglobulin and soluble P-selectin in hypertensive is present in hypertension. This may be a contributing patients and normotensive controls. Both markers were factor to the link between this risk factor and the develraised in the patients (P Ͻ 0.05), and in a subgroup of opment of thrombotic disease such as stroke. patients, beta thromboglobulin was reduced with sucKeywords: soluble P-selectin; beta thromboglobulin; platelets second was a study of 40 patients with newly-diag-
Introduction
nosed hypertension (mean SBP 165 mm Hg, mean A major consequence of hypertension is stroke.
DBP 107 mm Hg, 32 men, mean age 48 years). Beta However, it is curious that these strokes are often of thromboglobulin was measured by Amersham RIA thrombotic/occlusive origin, and not haemorrhagic (Amersham, UK) and this study was controlled by origin. It has therefore been hypothesised that this plasma from 22 normotensive (mean blood pressure may be related to changes in thrombosis and haemo-135/74 mm Hg), age (45 years) and sex (15 men) stasis (eg, levels of fibrinogen, cross-linked fibrin Dmatched controls. Twenty of the patients were dimer) in patients with hypertension. An additional treated with the angiotensin-converting enzyme manifestation of these changes which could promote (ACE) inhibitor quinapril 10 mg daily. A second thrombosis may also be inappropriate changes in plasma sample was obtained from the same patients platelet physiology such as excess activation and after 12 weeks, when BP had fallen significantly to increased volume, as is known in ischaemic heart a mean of systolic 151 mm Hg (P Ͻ 0.05) and diasdisease and stroke. 1 Increased plasma levels of platetolic 98 mm Hg (P Ͻ 0.05). All subjects were let specific products soluble P-selectin (a component asymptomatic for vascular disease and were also of the alpha granule membrane) and beta thrombogfree of complications such as diabetes, renal and lobulin (a constituent of the alpha granule matrix) liver disease, or connective tissue disease. are taken to imply increased platelet activation. 2, 3 We therefore aimed to determine whether or not Statistics patients with hypertension would have evidence of platelet activation as defined by increases in these Data between patients and controls was analysed by soluble plasma markers.
the Mann-Whitney U test. Data at two time points was analysed by paired t-testing. Correlations were by Spearman's ranks method.
Subjects and methods
We measured soluble P-selectin in citrated plasma
Results
and beta thromboglobulin in CTAD plasma (a cocktail of citrate, theophylline, adenosine and dipyridaIn the cross-section study, soluble P-selectin in the mole designed to minimise ex vivo platelet acticitrated plasma of the patients was median vation: Diatube, Diagnotica Stago, France) by 300 ng/mL, range 190-800 ng/mL. In the controls it commercial immunoassay in two separate studies.
was median 228, range 175-412 ng/mL (P Ͻ 0.05, The first was a cross-sectional study of 100 patients Figure 1 ). 40-77 ng/mL) in the patients and 32 ng/mL (95% mm Hg, 30 men, mean age 52 years) age and sex CI 27-36 ng/mL) in 22 controls (P Ͻ 0.01, Figure 2 ). matched controls. Soluble P-selectin was measured Again, there were no Spearman rank correlations by the Takara Shuzo ELISA (Honshu, Japan). The with either SBP or DBP. After 12 weeks treatment with quinapril, mean BP in the 20 patients dropped to 151/98 (P Ͻ 0.05). This was accompanied by a reduction in plasma beta Correspondence: Dr AD Blann thromboglobulin from a median of 69 ng/mL (95% profile in the response of platelets to ex vivo aggre-CI 45-106 ng/mL) to a median of 46 ng/mL (95% CI gation by adrenaline, ADP and collagen. We cannot 35-60 ng/mL) (P Ͻ 0.05).
say if this effect is likely to be constant for any particular therapy as we and others have used only ACE inhibitors.
Discussion
Together, changes may be at least partly responThe majority of strokes due to hypertension are sible for the increased risk of thrombotic stroke and thrombotic, implicating changes in thrombosis, haeindicates that therapeutic strategies aimed at reducmostasis and/or platelet function. Beta thromboglobing platelet activity (such as the use of aspirin) may ulin and soluble P-selectin are plasma markers of be beneficial. platelet activation.
2,3 Therefore, the raised levels in essential hypertension we have found suggests
